Cargando…

Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors

BACKGROUND: Immune checkpoint inhibitors (ICIs) has emerged as a popular cancer treatment approach. However, non-specific activation of T cells by ICIs can lead to immune-related adverse events (irAEs), including specific rheumatic manifestations. The study aimed to explore the current trend of ICIs...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Li, Ma, Gang, Chen, Kai, Zhou, Qiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587544/
https://www.ncbi.nlm.nih.gov/pubmed/37869006
http://dx.doi.org/10.3389/fimmu.2023.1242336
_version_ 1785123388345286656
author Zeng, Li
Ma, Gang
Chen, Kai
Zhou, Qiao
author_facet Zeng, Li
Ma, Gang
Chen, Kai
Zhou, Qiao
author_sort Zeng, Li
collection PubMed
description BACKGROUND: Immune checkpoint inhibitors (ICIs) has emerged as a popular cancer treatment approach. However, non-specific activation of T cells by ICIs can lead to immune-related adverse events (irAEs), including specific rheumatic manifestations. The study aimed to explore the current trend of ICIs associated rheumatic irAEs and summarize the knowledge structure through bibliometric methods. METHODS: The Web of Science Core Collection database (WoSCC) was selected for retrieving literature on ICIs associated rheumatic irAEs. To evaluate contributions from different countries/regions, institutions, journals, and authors, bibliometric analysis software, including VOSviewer and CiteSpace, as well as bibliometric online platforms, were utilized to construct and visualize bibliometric networks. Through the systematic review of this knowledge domain, future research directions were determined. RESULTS: In This study, a total of 803 publications on ICIs-associated rheumatic irAEs were included for analysis. The distribution of these publications revealed two distinct growth phases: a stable phase between 2007 to 2015 followed by rapid growth from 2016 to 2020. The United States emerged as the top contributor in terms of publications, citations, and h-index, with the majority of leading institutions and funding agencies located there. Apart from government funding, pharmaceutical companies such as Bristol Myers Squibb and Merck Company also play a significant role in drug development and research. Analysis of keywords and citation bursts indicated that the initial burst was related to “monoclonal antibody,” “anti-CLTA4 antibody,” and “melanoma”. This was followed by a rise in interest related to “sarcoidosis,” “safety,” “inflammatory arthritis,” and “preexisting autoimmune.” CONCLUSION: This study summarized the global research trends concerning ICIs associated rheumatic irAEs. The findings can provide valuable insights into the current understanding of rheumatic irAEs, highlight the research trend and developments in the field. Future efforts should focus on developing classification criteria and guidelines, conducting prospective studies, investigating the mechanisms involved, and identifying biomarkers for prediction and monitoring of these events.
format Online
Article
Text
id pubmed-10587544
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-105875442023-10-21 Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors Zeng, Li Ma, Gang Chen, Kai Zhou, Qiao Front Immunol Immunology BACKGROUND: Immune checkpoint inhibitors (ICIs) has emerged as a popular cancer treatment approach. However, non-specific activation of T cells by ICIs can lead to immune-related adverse events (irAEs), including specific rheumatic manifestations. The study aimed to explore the current trend of ICIs associated rheumatic irAEs and summarize the knowledge structure through bibliometric methods. METHODS: The Web of Science Core Collection database (WoSCC) was selected for retrieving literature on ICIs associated rheumatic irAEs. To evaluate contributions from different countries/regions, institutions, journals, and authors, bibliometric analysis software, including VOSviewer and CiteSpace, as well as bibliometric online platforms, were utilized to construct and visualize bibliometric networks. Through the systematic review of this knowledge domain, future research directions were determined. RESULTS: In This study, a total of 803 publications on ICIs-associated rheumatic irAEs were included for analysis. The distribution of these publications revealed two distinct growth phases: a stable phase between 2007 to 2015 followed by rapid growth from 2016 to 2020. The United States emerged as the top contributor in terms of publications, citations, and h-index, with the majority of leading institutions and funding agencies located there. Apart from government funding, pharmaceutical companies such as Bristol Myers Squibb and Merck Company also play a significant role in drug development and research. Analysis of keywords and citation bursts indicated that the initial burst was related to “monoclonal antibody,” “anti-CLTA4 antibody,” and “melanoma”. This was followed by a rise in interest related to “sarcoidosis,” “safety,” “inflammatory arthritis,” and “preexisting autoimmune.” CONCLUSION: This study summarized the global research trends concerning ICIs associated rheumatic irAEs. The findings can provide valuable insights into the current understanding of rheumatic irAEs, highlight the research trend and developments in the field. Future efforts should focus on developing classification criteria and guidelines, conducting prospective studies, investigating the mechanisms involved, and identifying biomarkers for prediction and monitoring of these events. Frontiers Media S.A. 2023-10-06 /pmc/articles/PMC10587544/ /pubmed/37869006 http://dx.doi.org/10.3389/fimmu.2023.1242336 Text en Copyright © 2023 Zeng, Ma, Chen and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zeng, Li
Ma, Gang
Chen, Kai
Zhou, Qiao
Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors
title Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors
title_full Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors
title_fullStr Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors
title_full_unstemmed Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors
title_short Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors
title_sort bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587544/
https://www.ncbi.nlm.nih.gov/pubmed/37869006
http://dx.doi.org/10.3389/fimmu.2023.1242336
work_keys_str_mv AT zengli bibliometricanalysisofrheumaticimmunerelatedadverseeventsassociatedwithimmunecheckpointinhibitors
AT magang bibliometricanalysisofrheumaticimmunerelatedadverseeventsassociatedwithimmunecheckpointinhibitors
AT chenkai bibliometricanalysisofrheumaticimmunerelatedadverseeventsassociatedwithimmunecheckpointinhibitors
AT zhouqiao bibliometricanalysisofrheumaticimmunerelatedadverseeventsassociatedwithimmunecheckpointinhibitors